This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?
by Zacks Equity Research
Stryker's (SYK) Neurotech business goes strong, VEXIM buyout likely to boost segment.
Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?
by Zacks Equity Research
Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.
Stryker Loses 7.6% in a Month: What's Weighing It Down?
by Zacks Equity Research
Stryker's (SYK) declining margins and demand for healthcare products raise concern.
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.
Stryker Closes Entellus Buyout, Bolsters Neurotechnology Line
by Zacks Equity Research
Stryker (SYK) maintains its acquisition-driven strategy to provide superior and more economic patient experiences.
Stryker (SYK) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Stryker's (SYK) Q4 results benefit from Mako product platform and higher organic sales.
MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN
by Zacks Equity Research
The Medical sector is expected to stand out on favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, and a value-based payment system.
Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.
Top Research Reports for Microsoft, Philip Morris and 3M
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Philip Morris (PM) and 3M (MMM).
MedTech Tax Resumes in 2018, 3 Stocks to Suffer
by Zacks Equity Research
Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.